Sector News

ConvaTec makes first acquisition since IPO

January 4, 2017
Life sciences

ConvaTec, the wound dressings manufacturer, has bought Dutch rival Eurotec Beheer for €25m (£21.3m), in the company’s first acquisition since listing on the stock market in October.

Reading-based ConvaTec was valued at more than £4bn when it went public, making it the biggest flotation on the London stock market last year and the largest ever European healthcare listing.

A major reason behind the decision to go public was to raise the company’s profile to drive ambitious growth plans, which include expanding into new markets and launching more products.

EuroTec, which was founded in 1996, manufactures and distributes ostomy systems and accessories on the continent and is the only manufacturer of these products in the Netherlands.

Ostomy care is an area of medicine in which patients have pouches fitted to their abdomens to drain urine or stools, such as a colostomy bag.

Paul Moraviec, chief executive of ConvaTec, said the acquisition would strengthen the company’s ostomy business in France and the Benelux region, two areas he said were “important pillars of the growth strategy for our ostomy care franchise”. The acquisition also includes EuroTec’s production facilities in the Netherlands.

FTSE 100-listed ConvaTec also makes dressings to contain oozing wounds, endotracheal tubes, catheters, surgical suction devices and faecal incontinence equipment.

The company’s products help people with long-term illnesses and the market is growing, driven by increasing life expectancy and greater incidence of chronic health conditions.

ConvaTec was founded in 1978, has 9,000 employees and operates in more than 100 countries. In the UK, it employs 1,000 staff and carries out all of its R&D work in North Wales.

Avista and Nordic Capital bought ConvaTec from US pharmaceuticals giant Bristol-Myers Squibb in 2008 for $4.1bn (£3.18bn) and remain shareholders.

By Julia Bradshaw

Source: The Telegraph

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach